



Page 1 of 1

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 60726-A/ JPW/ GJG/CSN		Serial No. 09/885,227	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicants: Moses Rodriguez and Daren Ure			
		Filing Date June 20, 2001		Group Art Unit 1646							
<b>U.S. PATENT DOCUMENTS</b>											
Examiner Initial		Document Number				Date	Name		Class	Subclass	Filing Date if Appropriate
/	OC	US	3	9	9	1	2	1	0	11/09/76	Shea
/	OC	US	20	02	00	37	84	8	A1	03/28/02	Eisenbach-Schwartz et al.
/		US	20	03	00	04	09	9	A1	01/02/03	Eisenbach-Schwartz et al.
/		US	09	8	7	5	4	2	9	06/05/01	Yong et al.
<b>FOREIGN PATENT DOCUMENTS</b>											
		Document Number				Date	Country	Class	Subclass	Translation	
										Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>											
/		Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease". <u>Current Opin. Immunol.</u> , 2000, <u>12</u> (6): 704-711.									
OC		Pender et al., <u>Int. Med. Journal</u> , 2002, <u>32</u> : 554-563.									
/		Van Noort et al., <u>International Review of Cytology</u> , 1995, <u>178</u> : 127-205.									
/		Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984, 933.									
EXAMINER		DATE CONSIDERED				10/28/03					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Applicants: Moses Rodriguez and Daren Ure  
U.S. Serial No. 09/885,227  
Filed: June 20, 2001  
**Exhibit A**

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
60726-ASerial No.  
09/885,227INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

OCT 22 2001

C5B

Applicants

Moses Rodriguez and Daren Ure

Filing Date  
June 20, 2001Group Art Unit  
1614 1646 04

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
	US	S	5	5	4	3	7	2	9/10/96	Hunter et al.		
	US	S	5	8	3	0	3	1	12/10/96	Stern		
	US	S	6	2	3	0	5	2	4/22/97	McLean et al		
	US	S	7	3	4	0	2	3	3/31/98	Bishwajit et al.		
DC	US	S	8	8	6	1	5	6	3/23/99	McLean et al		
	US	S	9	3	6	2	1	6	1	Konfino et al		
	US	09	4	8	7	7	0	3	1/20/00	EISENBACK - SCHWARTZ et al		
	US	09	6	2	0	2	1	6	7/20/02	EISENBACK - SCHWARTZ et al.		
	US	09	7	6	5	3	0	1	1/22/01	EISENBACK - SCHWARTZ et al		
	US	09	7	6	5	6	4	4	1/22/01	EISENBACK - SCHWARTZ et al.		

RECEIVED

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		WO 9 2 0 2 5 4 3	2/20/92	Europe				
		WO 9 4 0 3 4 8 4	2/17/94	US				
		WO 9 4 2 6 7 7 4	11/24/94	US				
DC		WO 9 5 2 6 9 8 0	10/12/95	US				
		WO 9 5 3 1 9 9 7	11/30/95	US				
		WO 0 1 5 2 8 7 8	7/26/01	US				
		WO 0 1 9 3 8 9 3	12/3/01	US				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	Ju et al., "Idiotypic Analysis of Antibodies Against the Terpolymer L-glutamic Acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT Idiotype Following Immunization with Various Synthetic Polymers Containing Glutamic Acid and Tyrosine", <u>Eur. J. Immunol.</u> , 1979, 9 (7): 553-560 (Abstract)
DC	Schwartz et al., "Gene Complementation in the T Lymphocyte Proliferative Response to Poly (Glu <sup>5</sup> Lys <sup>38</sup> Tyr <sup>5</sup> ): Evidence for Effects of Polymer Handling and Gene Dosage", <u>J. Immunol.</u> , 1979, 123 (1): 272-278 (Abstract)
DC	Baxevanis et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu <sup>5</sup> Ala <sup>6</sup> ) and Poly (Glu <sup>5</sup> Lys <sup>14</sup> Tyr <sup>15</sup> ): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", <u>Immunogenetics</u> , 1980, 11: 617-628

EXAMINER

Mayer

DATE CONSIDERED

04/03/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-A	Serial No. 09/885,227
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Applicants Moses Rodriguez and Daren Ure	
OCT 22 2002 AUFMAHRSERVICE		Filing Date June 20, 2001	Group Art Unit 1614 1646 OC

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Maurer et al., "Interpretations of Immune Responses of Mice to Poly(Glu60Lys40), its Modified Derivatives, and the Terpolymers Poly(Glu55Lys37Leu8) and Poly (Glu56Lys37Ser7)", Clin. Immunol. Immunopathol., 1980, 15(3): 344-356 (Abstract)

Herzenberg et al., "Lack of Immune Response Gene Control for Induction of Epitope-specific Suppression by TGAL Antigen", Nature, 1982, 295: 329-331 (Abstract)

Babu et al., "Reevaluation of Response Patterns of Nonresponder Mice to GlPhe Polymers", Immunogen., 1983, 18(1): 97-100 (Abstract)

Babu et al., "Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", J. Immunogenet., 1984, 11(3-4): 251-254

Falo et al., "Analysis of Antigen Presentation by Metabolically Inactive Accessory Cells and Their Isolated Membranes", Proc. Natl. Acad. Sci. USA, 1985, 82(19): 6647-6651 (Abstract)

Trannoy et al., "Epitope-specific Regulation of the T Cell Repertoire: Carrier Recognition in Association with I-E or I-A Does Not Influence the Restriction of Hapten-Specific T Cells", Eur. J. Immunol., 1985, 15(12): 1215-1221 (Abstract)

Lai et al., "Complementation of Class II a Alleles in the Immune Response to (Glulystyr) Polymers", Exp. Clin. Immunogenet., 1986, 3(1): 38-48 (Abstract)

Lai et al., "Monoclonal T Cell Responses to Two Epitopes on a Single Immunogen Controlled by Two Distinct Genes", J. Immunol., 1986, 136(10): 3799-3804 (Abstract)

De Kruyff et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", Eur. J. Immunol., 1987, 17 (8): 1115-1120 (Abstract)

Matsunaga et al., "Complementation of Class II A Alleles in the Immune Response to (Glu-Lys-Tyr) Polymers", Yokohama Med. Bull., 1988, 39(1-2): 9-19 (Abstract)

Zisman et al., "Direct Binding of a Synthetic Multichain Polypeptide to Class II Major Histocompatibility Complex Molecules on Antigen-presenting Cells and Stimulation of a Specific T-cell Line Require Processing of the Polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)

Deeb et al., "Comparision of Freund's and Ribi Adjuvants for Inducing Antibodies to the Synthetic Antigen (TG)-AL in Rabbits", J. Immunol. Methods, 1992, 152(1): 105-113 (Abstract)

Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH<sub>2</sub>-Terminal Including Proline as a Stop Signal for Trimming", J. Immunol., 1993, 151: 4732-4742

EXAMINER <i>Clayton</i>	DATE CONSIDERED	04/09/03
----------------------------	-----------------	----------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. If initial through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeOCT 22 2002  
C58  
U.S. PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Atty. Docket No.  
60726-ASerial No.  
09/885,227Applicants  
Moses Rodriguez and Daren UreFiling Date  
June 20, 2001Group Art Unit  
1614 1646 OC

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Zisman et al., "Dichotomy Between the T and the B Cell Epitopes of the Synthetic Polypeptide (T,G)-A-L", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract)

Asakura and Rodriguez, "A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination", Multiple Sclerosis, 1998, 4: 217-221

Asakura et al., "Targeting of IgM<sub>x</sub> Antibodies to Oligodendrocytes Promotes CNS Remyelination", J. Neurosci., 1998, 18(19): 7700-7708

Li et al., "Glatiramer Acetate Blocks the Activation of THP-1 Cells by Interferon- $\gamma$ ", Eur. J. Pharmacol., 1998, 342: 303-310

Pavelko et al., "Acceleration in the Rate of CNS Remyelination in Lyssolecithin-Induced Demyelination", J. Neurosci., 1998, 18(7): 2498-2505

Rodriguez, Neurological Therapeutics, 1998, 15(3): 245-250

Cohen, "Fundamental Immunology", Systemic Autoimmunity, 4<sup>th</sup> Ed., 1999, 1083

Fridkis-Hareli et al., "Binding of Random Copolymers of Three Amino Acids to Class II MHC Molecules", Intl. Immunol., 1999, 11(5): 635-641

McGavern et al., "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis", The Neuroscientist, 1999, 5(1): 19-28

Bieber et al., "Antibody-Mediated Remyelination: Relevance to Multiple Sclerosis", Multiple Sclerosis, 2000, 6: S1-S5

Henry, Celia M., "Special Delivery", Chem. and Eng. News, Sept. 18, 2000, 49-54

Warrington et al., "Human Monoclonal Antibodies Reactive to Oligodendrocytes Promote Remyelination in a Model of Multiple Sclerosis", Neurobiology, 2000, 97(12): 6820-6825

Bieber et al., "Humoral Autoimmunity as a Mediator of CNS Repair", Trends in Neurosci., 2001, 24(11): S39-S44

Warrington et al., "Immunoglobulin-Mediated CNS Repair", J. Allergy Clin. Immunol., 2001, S121-S125

RECEIVED

OCT 23 2002

TECH CENTER 1600/2900

EXAMINER *Allen*

DATE CONSIDERED

04/09/03

1600/2900

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeArt. Docket No.  
60726-ASerial No.  
09/885,227INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

## Applicants

Moses Rodriguez and Darren Ure

Filing Date  
June 20, 2001Group Art Unit  
1614 1646

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US 3 8 4 9 5 5 0	11/19/74	Teitelbaum et al.			
	US 4 3 3 9 4 3 1	7/13/82	Gaffar			
OC	US 5 2 0 4 0 9 9	4/20/93	Barbier et al.			
/	US 5 5 9 1 6 2 9	1/7/97	Rodriguez et al.			
/	US 5 6 2 7 2 0 6	5/6/97	Hupe et al.			
/	US 5 6 6 8 1 1 7	9/16/97	Shapiro et al.			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 8 8 1 0 1 2 0	12/29/88	US				
	WO 9 5 3 1 9 9 0	11/30/95	US				
OC	WO 9 5 3 3 4 7 5	12/14/95	Europe				
/	WO 9 8 3 0 2 2 7	7/16/98	US				
/	WO 0 0 0 5 2 5 0	2/3/00	US				
/	WO 0 0 1 8 7 9 4	4/6/00	US				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Israel J. Med. Sci.</u> , 1971, 7, 630-631 (Abstract)
	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Eur. J. Immunol.</u> , 1971, 1, 242-248
OC	Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", <u>Israel J. Med. Sci.</u> , 1972, 8, 1759-1760
/	Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", <u>Nature</u> , 1972, 240, 564-566
/	Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u> , 1972, 8, 656-657
/	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", <u>Eur. J. Immunol.</u> , 1973, 3, 273-279

EXAMINER


*Heunifield*

DATE CONSIDERED

04/05/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeApp. Docket No.  
60726-ASerial No.  
09/885,227O P E R A T I O N  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren UreFiling Date  
June 20, 2001Group Art Unit  
1614 1646 OC

## U.S. PATENT DOCUMENTS

Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US 5 7 1 9 2 9 6	2/17/98	Acton III, et al.			
	US 5 8 0 0 8 0 8	9/1/98	Konfino et al.			
	US 5 8 5 8 9 6 4	1/12/99	Aharoni et al.			
	US 5 9 8 1 5 8 9	11/9/99	Konfino et al.			
OC	US 5 9 5 8 9 7 2	9/28/99	Hupe et al.			
	US 6 0 4 8 8 9 8	4/11/00	Konfino et al.			
	US 6 0 5 4 4 3 0	4/25/00	Konfino et al.			
	US 6 2 1 4 7 9 1	4/10/01	Amon et al.			
	US 6 3 4 2 4 7 6	1/29/02	Konfino et al.			

TECH CENTER 1600  
OCT 24 2002  
RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		WO 0 2 0 0 1 0	4/13/00	US				
OC		WO 0 2 7 4 1 7	5/18/00	US				
		WO 0 0 5 2 4 9	2/3/00	US				
		WO 0 1 8 5 7 9 7	11/15/01	US				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Webb, et al., "In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis", <i>Eur. J. Immunol.</i> , 1973, 3, 279-286
	Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", <i>Israel J. Med. Sci.</i> , 1974, 10(9), 1172-1173
OC	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <i>Clin. Immunol. Immunopath.</i> , 1974, 3, 256-262
	Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", <i>Isr. J. Med. Sci.</i> , 1975, 11, 1388 (Abstract)
	Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", <i>Immunochem.</i> , 1976, 13, 333-337
	Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", <i>J. Neurol. Sci.</i> , 1977, 31, 433-438

EXAMINER


*Ellenby*

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227O P E  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren Ure  
Filing Date  
June 20, 2001Group Art Unit  
1614 1646 OC

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	SEARCH CENTER 1600/2000	RECEIVED
	US 20010055568 A1	12/27/01	Gilbert et al.					OCT 22 2002
OC	US 09359099	7/22/99	Strominger et al.					
	US 09405743	9/24/99	Gad et al.					
	US 09768872	1/23/01	Aharoni et al.					
	US 09816989	3/23/01	Gad et al.					

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 0160392	8/23/01	US				
OC	WO 0193828	12/13/01	US				
	WO 0197846	12/27/01	US				
/	EP 0383620	8/22/90	Europe				
/	EP 0359783	11/29/95	Europe				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel J. Med. Sci.</u> , 1977, 13, 1038 (Abstract)
	Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", <u>Neurol.</u> , 1978, 28, 336 (Abstract)
	Sela, et al., "Experimental Allergic Encephalomyelitis" in <u>Menarini Series on Immunopathology</u> , vol. 1, <u>First Symposium of Organ Specific Autoimmunity</u> , Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21
OC	Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", <u>Ann. Neurol.</u> , 1979, 6, 469-473
	Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" <u>J. Neurol. Sci.</u> , 1979, 42, 267-274
	Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>J. Immunol.</u> , 1979, 123, 2156-2160 (Abstract)
	Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", <u>Israel J. Med. Sci.</u> , 1979, 15, 868-869 (Abstract)


EXAMINER *M. A. Ure*

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)TECH C 1  
CONSIDER 2  
1600 2002  
RE 3  
4  
5  
6  
7  
8

RE

Sheet 4 of 12

App. Docket No.	Serial No.
09/26-A	09/885,227
Applicants	
Moises Rodriguez and Daren Ure	
Filing Date	Group Art Unit
June 20, 2001	1614 1646 OC

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in <u>Cell Biology and Immunology of Leukocyte Function</u> (Academic Press, New York, 1979) 681-685
	Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613
	Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogs" in <u>The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis</u> (Academic Press, New York, 1980) 105-107
	Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in <u>Progress in Multiple Sclerosis Research</u> (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418
	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Ann. Neurol.</u> , 1980, 8, 117 (Abstract)
OC	Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", <u>Trans. Am. Neurol. Assoc.</u> , 1980, 105, 348-350
	McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>J. Neurol. Sci.</u> , 1980, 46, 137-143
	Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", <u>Immunological Rev.</u> , 1981, 55, 5-30
	Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", <u>Ann. Neurol.</u> , 1982, 11, 317-319
	Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", <u>J. Neuropath. Exp. Neurol.</u> , 1983, 42, 356 (Abstract)
	Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", <u>J. Neurol. Sci.</u> , 1983, 62, 281-293
	Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", <u>Ann. N.Y. Acad. Sci. (USA)</u> , 1984, 366-372
	Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonset et al., <u>Immunological and Clinical Aspects of Multiple Sclerosis</u> (MTP Press, The Hague, 1984) 144-150

EXAMINER *Chayupasw*

DATE CONSIDERED

04/05/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OCT 24 2002

TECH CENTER 1600/2900

Sheet 5 of 12

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227O P E  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren UreFiling Date  
June 20, 2001Group Art Unit  
1614 1646 OC

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", Ann. N.Y. Acad. Sci. (USA), 1984, 436, 498-499

Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", Neurol., 1985, 35 (Suppl. 1), 103 (Abstract)

Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", Neurol., 1985, 35, 1754-1759

Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", Neurol., 1985, 35 (Suppl. 1), 170 (Abstract)

Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in Proc. 7<sup>th</sup> Eur. Immunol. Mtg., Jerusalem, September 8-13, 1985 (Abstract)

Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", Immunol. Today, 1985, 6(4), 141

Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", Neurol., 1986, 36, 92-94

Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", Adv. Ther. (USA), 1987, 4, 206 (Abstract)

Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 408-414

Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396

Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444

Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250

Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", Neurol., 1988, 38(Suppl. 2), 69-71

Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", Neurol., 1988, 38(Suppl. 2), 66-69

Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", Proc. Natl. Acad. Sci. USA, 1988, 85, 9724-9728

EXAMINER *Clayton*

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227

RECEIVED

O I P A  
OCT 27 2002  
PATENT & TRADEMARK OFFICEINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

OCT 24 2002

TECH CENTER 1600/2000

OCT 24 2002

Applicants  
Moses Rodriguez and Daren Ure  
Filing Date  
June 20, 2001Group Art Unit  
1614 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ferrara, et al., "Graft-Versus-Host Disease", New Eng. J. Med., 1991, 324, 667-674

Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", J. Neurol., 1991 (Suppl. 1) (Abstract)

Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 2, 527-565

Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract)

Teitelbaum et al., "Cross-reactions and Specificities of Monoclonal Antibodies Against Myelin Basic Protein and Against the Synthetic Copolymer 1", Proc. Natl. Acad. Sci. (USA), 1991, 88, 9528-9532

Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", Transplantation, 1991, 52, 15-20

Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198

OC Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in Congress for Advances in the Understanding and Treatment of Multiple Sclerosis, Boston (USA), Oct. 28-29, 1992

Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", Israel J. Med. Sci., 1992, 28, 486 (Abstract)

Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84

Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137-141

Weinshenker et al., "Natural History and Treatment of Multiple Sclerosis", Current Opinion in Neurol. and Neurosurgery, 1992, 5, 203-211

Aharoni et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", Eur. J. Immunol., 1993, 23, 17-25

EXAMINER

Humphrey

DATE CONSIDERED

04/05/03


\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OCT 24 2002

TECH CENTER 1600/2900

Sheet 6 of 12

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Atty. Docket No.  
60726-ASerial No.  
09/885,227

## Applicants

Moses Rodriguez and Daren Ure

Filing Date  
June 20, 2001Group Art Unit  
1614 1646 OC

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689

Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis, Roma (Italy), September 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232

Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" J. Israel Med. Assoc., 1989, CXVI(9), 453-456

Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in Handbook of Multiple Sclerosis (S.D. Cook Marcel Rekker, ed., 1990) 469-480

Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", Drug Therapy, 1990, 31-32, 37-39, 42-43

Oc Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", Int. Immunol., 1990, 2(8), 713-718

Kay, et al., "The Mechanism of Action of FK 506", Transplantation Proceedings, 1990, 22(1, Suppl. 1), 96-99

Lee, et al., "Peptide and Protein Drug Delivery" in Advances in Parenteral Sciences (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695

Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", Neurologic Clinics, 1990, 8(1), 119-141

Sela, et al., "Suppressive Activity of COP-1 in EAE and its Relevance to Multiple Sclerosis", Bull. Inst. Pasteur, 1990, 88, 303-314

Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5

Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" Neur. Neurochir. Pol., 1990, 24, 113

Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", Neurol., 1991, 41, 533-539

Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", Neurol., 1991, 41, 1317-1319

Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991

EXAMINER *Clayton*

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227OPI INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren Ure  
Filing Date  
June 20, 2001Group Art Unit  
1614 1646

PATENT &amp; TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u> , 1993, <u>29</u> , 175-181
Arnon, et al., "On the Existence of Suppressor Cells", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>100</u> , 2-7
Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993
Francis, "The Current Therapy of Multiple Sclerosis", <u>J. Clin. Pharmacy and Therapeutics</u> , 1993, <u>18</u> , 77-84
Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", <u>Int. Arch. Allergy Immunol.</u> , 1993, <u>102</u> , 309-320
Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones", <u>Israel J. Med. Sci.</u> , 1993 (Abstract)
Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two-year Follow-up", in <u>9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis</u> , Florence (Italy), October-November, 1993, 48 (Abstract)
Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in <u>The IBC Conference on Multiple Sclerosis</u> , San Diego (USA), December 10, 1993 (Abstract)
Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", <u>Makromol. Chem. Macromol. Symp.</u> , 1993, <u>70/71</u> , 147-155
Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", <u>Therapeutic Immunol.</u> , 1994, <u>1</u> , 65-70
Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", <u>Seminars in Neurol.</u> , June 1994, <u>14</u> (2), 146-153
The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, <u>241</u> (Suppl. 1), 6
Cotton, "Options for Multiple Sclerosis Therapy", <u>J.A.M.A. Medical News &amp; Perspectives</u> , 1994, <u>272</u> (18), 1393
Dorling, et al., "Prospects for Xenografting", <u>Curr. Opinions Immunol.</u> , 1994, <u>6</u> , 765-769

EXAMINER M. Schow

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

TECH CENTER 1600/2900

11 24 2002

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No.  
60726-ASerial No.  
09/885,227

## Applicants

Moses Rodriguez and Daren Ure

Filing Date  
June 20, 2001Group Art Unit  
1614 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", Department of Chemical Immunology, The Weizmann Institute of Science, 1994
	Fridkis-Hareli, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91, 4872-4876
	Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Israeli Biochem. Soc., 1994, 21-22 (Abstract)
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Neurochem Mtg., August 14-19, 1994
61	Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", J. Neurochem., 1994, 53 (Suppl. I), 561
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", Israeli Immunol. Soc., May 3-4, 1994 (Abstract)
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, 1994
	Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236
	Jacobs et al., "Advances in Specific Therapy for Multiple Sclerosis", Neurol., 1994, 7, 250-254
	Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", Ann. Neurol., 1994, 36 (Suppl.), 115-117
	Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", Israel Neurological Assoc., December 19-20, 1994, Herzliya (Israel), 17

EXAMINER

*Clayton*


DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with communication to applicant.

RECEIVED

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren UreFiling Date  
June 20, 2001Group Art Unit  
1614 1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in <u>Encycl. Molecular Bio</u> . (Oxford Blackwell Science Ltd, 1994) 602-606
	Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", <u>Neurol.</u> , 1994, <u>44</u> (Suppl. 2), A212
	Milo, et al., "Additive Effect of Copolymer-1 and Interferon- $\beta$ on the Immune Response to Myelin Basic Protein", <u>Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine</u> , 1994, 22
	Milo, et al., "Copolymer-1 and Interferon- $\beta$ Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", <u>J. Neuroimmunol.</u> , 1994, <u>54</u> , 183 (Abstract)
OC	Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", <u>Am. Family Physician</u> , 1994, <u>50</u> (4), 845-847
	Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", <u>Blood</u> , 1994, <u>84</u> (8), 2802-2810
	Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", <u>Ann. Neurol.</u> , 1994, <u>36</u> , 114-115
	Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", <u>Neurol.</u> , 1994, <u>44</u> (Suppl. 2), A358
	Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 1994, <u>91</u> , 437-438
	Milo, et al., "Additive Effects of Copolymer-1 and Interferon $\beta$ -1b on the Immune Response to Myelin Basic Protein", <u>J. Neuroimmunol.</u> , 1995, <u>61</u> , 185-193
	O'Connor, et al., "Powders" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1598-1614
	Porter, "Coating of Pharmaceutical Dosage Forms," in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1650-1659
	Reilly, Jr., W.J., "Pharmaceutical Necessities" in <u>The Science and Practice of Pharmacy</u> , Remington, 1995, <u>2</u> , 1380-1416
	Schlegel, et al., "Inhibition of Allore cognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in <u>Am. Soc. Hematology, 37<sup>th</sup> Annual Meeting</u> , Seattle, WA (USA), December 1-5, 1995, 224a (Abstract)

EXAMINER

Mengler

DATE CONSIDERED

04/05/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with communication to applicant.

RECEIVED

Oct 24 2002

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)Applicants  
Moses Rodriguez and Daren UreFiling Date  
June 20, 2001Group Art Unit  
1614 1646 OC

OCT 22 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1-Nun, et al., "The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease", <u>J. Neurol.</u> , 1996, 243 (Suppl. 1), S14-S22
	Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", <u>Chemical Abstracts</u> , 1996, 125, 291993b
	Sykes, "Immunobiology of Transplantation", <u>Faseb J.</u> , 1996, 10, 721-730
	Teitelbaum, et al., "Copolymer 1 Inhibits Chronic Relapsing Experimental Allergic Encephalomyelitis Induced by Proteolipid Protein (PLP) Peptides in Mice and Interferes with PLP-specific T Cell Responses", <u>J. Neuroimmunol.</u> , 1996, 64, 209-217
	Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", <u>Immunol. Letters</u> , 1997, 58, 79-87
	Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", <u>J. Immunol.</u> , 1997, 158, 2471-2476
OC	Tarcic et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract)
	Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", <u>Israel J. Med. Sci.</u> , 1997, 33, 280-284
	Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", <u>J. Immunol.</u> , 1998, 160, 4386-4397
	Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-reactive T Cell Clones", <u>Proc. Natl. Acad. Sci.</u> , October 1998, 95, 12528-12531
	Cazzato, et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universita, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina. October 1999, 90(10), 538-544 (Abstract)
	Kepsutlu et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCPLUS AN: 1999: 590411, <u>Acta. Pol. Pharm.</u> 1999, 56(3), 227-235 (Abstract)
	Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy", <u>Ann. Neurol.</u> , 1999, 46: 253-253

EXAMINER

Clayton

DATE CONSIDERED

04/05/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

Oct 24 2002

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
60726-ASerial No.  
09/885,227INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Applicants

Moses Rodriguez and Daren Ure

OCT 22 2001  
PATENT & TRADEMARK  
Office

Filing Date

June 20, 2001

Group Art Unit

1614 1642

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

OC Fridkis-Hareli et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCPLUS AN: 2000:455053, Human Immunology, 2000, 61(7), 640-650 (Abstract)

OC Durelli, "Immunotherapeutics of Multiple Sclerosis", Instituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino, 467-475

1999 OC

10/09/03

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

EXAMINER

Munphy

DATE CONSIDERED

04/09/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.